PMC9480179_01
Clinical lesions of patient 1 and assessment index changes of all patients. (A) Lesion changes in patient 1 at baseline and at weeks 4, 16, and 20 of dupilumab injection. (B) Development in NRS, DLQI, ACT, and IGA-CPG scores in patient 1. (C) A mean score change in the NRS, DLQI, and IGA-CPG for patient 2-4.
CCID-15-1863-g0001.jpg
PMC9480179_01_CCID-15-1863-g0001.jpg
f0001
The lesions were typically nodular on the extremities and trunk (Figure 1A) with an NRS score of 10, a DLQI score of 26, and an IGA-CPG score of 4 (Figure 1B). At week 16, the patient's NRS dropped to 0 and the DLQI dropped to 5, as well as the IgE returned to the normal range with relief of the clinical lesions (Figure 1A). Until week 20, the ACT reached 23 (Figure 1B), and the frequency of salbutamol was reduced under the respiratory physician's direction.
PMC9480179_02
PMC9480179_03
PMC9480179_04